Darunavir Ethanolate CAS 635728-49-3 Puritas ≥99.0% API Factory Anti-HIV HIV Protease Inhibitor
| Nomen chemicum | Darunavir Ethanolate |
| Synonyma | DRV;Prezista;TMC114 Ethanolate;UNII-33O78XF0BW;N-[(1S,2R) -3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]acidi carbamici (3R,3aS,6aR)-hexahydrofuro [2,3-b]furan-3-yl ester compd.cum ethanol |
| CAS Number | 635728-49-3 |
| CATTUS Number | RF-API69 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C29H43N3O8S |
| M. Pondus | 593.73 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba vel Off-White Crystalline pulveris |
| Lepidium sativum IR | Correspondet spectrum Latin |
| Imprimis Rotationes | -0.5°~ +0.5° |
| Substantiae cognatae | (per HPLC) |
| Max Single immunitas | ≤0.20% |
| Totalis immunditias | ≤0.50% |
| Aquae (KF) | ≤1.0% |
| Residere in Ignition | ≤0.10% |
| Metalla gravis | ≤10ppm |
| Contentus Ethanol | ≤7.5% (GC) |
| RELICTUM Solvents | Methanol ≤0.30% |
| Puritas | ≥99.0% (HPLC) |
| Test Standard | Enterprise Standard |
| Consuetudinem | Darunavir Ethanolate HIV-1 Protease Inhibitor Anti-HIV Antiviral |
sarcina: Utrem, aluminium foil, pera, cardboard Drum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Darunavir Ethanolate (Prezista) est HIV protease inhibitor.Darunavir derivativae secundae generationis HIV-1-protease inhibitor;amprenavir constitutione similis.Antiviral.Productum investigationis COVID19 relatarum est.Infeliciter, DRV solubilitatem in aqua et pauper bioavailability habet humilem, ergo administrationem in gustatu relative requirit ut efficaciam therapeuticam exhibeat.Darunavir est latum spectrum potentem inhibitorem activum contra HIV-1 orci segregans cum cytotoxicitate minima.Darunavir vincula hydrogenii format cum atomis Asp29 et Asp30 protease principali conservatis.Hae interationes criticae proponuntur de potentia huius compositi contra HIV isolates, quae multiplicibus protease inhibitoribus repugnant.In studio vitro in MT-2 cellis, potentia darunavir maior est quam saquinavir, amprenavir, nelfinavir, indinavir, lopinavir et ritonavir.Darunavir imprimis ab enzymis hepaticis cytochromis P450 (CYP) metabolis, praesertim CYP3A.Dosis ritonavirorum "boosting" inhibitorem CYP3A agit, quo darunavir bioavailability augetur.Darunavir designatus est ut robusti interactiones cum protease enzyme ex multis modis HIV formare destinaretur, inclusis modis ab aegris peritis curationi cum multiplici resistentia mutati.
